Impact on financial performance from deliveries at undetermined prices and differences from quoted prices
First written in FY2021. . Latest entry: FY2026.
0 other companies' latest entry also says "Other".
- FY2026Improvement in the transaction price determination ratioAnnual report
「Of the ¥2.2 trillion in prescription pharmaceutical sales for the fiscal year ending March 2026, the transaction price determination ratio, on a value basis, was 99.7%, indicating a tendency for transaction prices to be almost finalized by the end of the fiscal year.」
The transaction price determination ratio improved to 99.7% from 99.5% in the fiscal year ended March 2025. The risk that differences from estimated prices could affect performance continues. - FY2025Decline in the transaction price determination ratioAnnual report
「Of the ¥2.1 trillion in prescription pharmaceutical sales for the fiscal year ended March 2025, the transaction price determination ratio, on a value basis, was 99.5%, indicating a tendency for transaction prices to be almost finalized by the end of the fiscal year.」
The transaction price determination ratio fell to 99.5% from 99.6% in the fiscal year ended March 2024. The risk that differences between undetermined prices and estimated prices could affect performance continues. - FY2023Decline in the transaction price determination ratioAnnual report
「Of the ¥2.1 trillion in prescription pharmaceutical sales for the fiscal year ended March 2023, the transaction price determination ratio, on a value basis, was 99.6%, indicating a tendency for transaction prices to be almost finalized by the end of the fiscal year.」
The transaction price determination ratio fell to 99.6% from 99.8% in the fiscal year ended March 2022. The risk that differences between undetermined prices and estimated prices could affect performance continues to be disclosed. - FY2022Slight decline in the transaction price determination ratioAnnual report
「Of the ¥2.1 trillion in prescription pharmaceutical sales for the fiscal year ended March 2022, the transaction price determination ratio, on a value basis, was 99.8%, indicating a tendency for transaction prices to be almost finalized by the end of the fiscal year. (Transaction price determination ratios for the past 3 years: fiscal year ended March 2019: 96.6%; fiscal year ended March 2020: 99.7%; fiscal year ended March 2021: 99.9%)」
The transaction price determination ratio remained high at 99.8%, but edged down from 99.9% in the previous fiscal year. - FY2021First statedAnnual report
「Accordingly, if a difference arises between the determined transaction price and the estimated price, it may affect the performance and financial condition of the wholesale business for prescription pharmaceuticals and other products. Of the ¥2.1 trillion in prescription pharmaceutical sales for the fiscal year ended March 2021, the transaction price determination ratio, on a value basis, was 99.9%, indicating a tendency for transaction prices to be almost finalized by the end of the fiscal year.」
The risk that differences between estimated prices and final prices negotiated after delivery to medical institutions could affect performance was newly disclosed separately, together with the 99.9% transaction price determination ratio.